|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000039546 |
|
最近更新日期: Date of Last Refreshed on: |
2021-04-05 16:16:57 |
|
注册时间: Date of Registration: |
2020-10-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
缺血修饰蛋白作为急性主动脉夹层定性诊断标记物的研究 |
|
Public title: |
The value of serum ischemia-modified albumin in early diagnosis of acute aortic dissection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
缺血修饰蛋白作为急性主动脉夹层定性诊断标记物的研究 |
|
Scientific title: |
The value of serum ischemia-modified albumin in early diagnosis of acute aortic dissection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周阳 |
研究负责人: |
柴湘平 |
|
Applicant: |
Zhou Yang |
Study leader: |
Chai Xiangping |
|
申请注册联系人电话: Applicant telephone: |
+86 18674875605 |
研究负责人电话:
Study leader's |
+86 17582497442 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhouzhou1107@csu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
345060078@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
研究负责人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
|
Applicant address: |
139 Middle Renmin Road, Furong District, Changsha, Hunan |
Study leader's address: |
139 Middle Renmin Road, Furong District, Changsha, Hunan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅二医院 |
||
|
Applicant's institution: |
The Second Xiangya Hospital, Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅二医院 |
||
|
Affiliation of the Leader: |
The Second Xiangya Hospital, Central South University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2018(S052) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅二医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Board of the Second Xiangya Hospital of Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2018-06-29 00:00:00 | ||
|
伦理委员会联系人: |
徐会中 |
||
|
Contact Name of the ethic committee: |
Xu Huizhong |
||
|
伦理委员会联系地址: |
湖南省长沙市芙蓉区人民中路139号 |
||
|
Contact Address of the ethic committee: |
139 Middle Renmin Road, Furong District, Changsha, Hunan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731-85292120 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
chaixiangping@csu.edu.cn |
|
研究实施负责(组长)单位: |
中南大学湘雅二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Xiangya Hospital, Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市芙蓉区人民中路139号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
139 Middle Renmin Road, Furong District, Changsha, Hunan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中南大学中央高校基本科研业务费专项资金资助 |
||||||||||||||||||||||
|
Source(s) of funding: |
Fundamental Research Funds for the Central Universities of Central South University |
||||||||||||||||||||||
|
研究疾病: |
主动脉夹层 |
||||||||||||||||||||||
|
Target disease: |
aortic dissection |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
探讨缺血修饰蛋白作为急诊主动脉夹层的定性诊断标记物。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigat ischemia-modifying protein as a qualitative diagnostic marker for acute aortic dissection. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
所有AAD患者均需行主动脉CTA确诊;AMI患者通过冠脉造影或心内科治疗过程确诊,并排除AAD;APE患者均通过肺动脉CTA确诊;AAD诊断标准参考2014年欧洲心脏病学会《主动脉疾病诊断与治疗指南》,APE诊断参考2019年《2019年APE诊断与治疗指南》。AMI诊断标准参考2018年《急性ST段抬高型心肌梗死诊断和治疗指南》。NNCP患者为排除AAD、AMI、APE等心源性胸痛。 |
||||||||||||||||||||||
|
Inclusion criteria |
All AAD patients need to be diagnosed by aortic CTA; AMI patients are diagnosed through coronary angiography or cardiology treatment, and AAD is excluded; APE patients are diagnosed through pulmonary artery CTA; AAD diagnostic criteria refer to the 2014 European Society of Cardiology "Aortic Disease Guidelines for Diagnosis and Treatment", APE diagnosis refers to the 2019 "Guidelines for Diagnosis and Treatment of APE" in 2019. The diagnostic criteria of AMI refer to the 2018 "Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction". NNCP patients were excluded from cardiogenic chest pain such as AAD, AMI, and APE. |
||||||||||||||||||||||
|
排除标准: |
年龄小于18岁、终末期患者(包括各种类型肿瘤的晚期、肝肾疾病的终末期、发病时间超过48h以上胸痛患者、妊娠患者、患者本人或家属不愿参加实验者) |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients younger than 18 years old and terminal patients (including patients with advanced stages of various types of tumors, terminal liver and kidney diseases, patients with chest pain more than 48 hours onset, pregnant patients, patients themselves or their family members who are unwilling to participate in the experiment). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-11-10 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-11-10 00:00:00 至 To 2022-12-31 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究为前瞻性队列研究,无随机分组,主要根据根据患者最后的诊断进行分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study is a prospective cohort study without random grouping, and grouping is mainly based on the final diagnosis of patients. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
发表在相关的杂志网页上或通过合理的申请向研究者索要,研究者邮箱zhouzhou1107@csu.edu.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Published on the web pages of relevant journals or requested by the researcher through a reasonable application, the researcher's email address zhouzhou1107@csu.edu.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
由两名医师分别从电子病例系统查阅患者的一般情况,记录患者的信息在excel表上进行分析。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Two doctors respectively consulted the general condition of the patient from the electronic medical record system, and recorded the patient's information for analysis on the excel sheet. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |